Print

DSM Biologics and Crucell N.V. (CRXL) Announce Record Achievement in PER.C6(R) Technology  
6/16/2008 12:01:38 PM

Heerlen/Leiden, The Netherlands, 16 June 2008 - DSM Biologics and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announce another breakthrough in the production of IgG antibodies using PER.C6® technology. By employing the PER.C6® human cell line and proprietary XD™ technology, a record yield of over 27 grams per liter has been achieved. In March 2008 a yield of 15 grams per liter was reported.
//-->